About Aurealis Therapeutics
Aurealis Therapeutics is a company based in Basel (Switzerland) founded in 2015.. Aurealis Therapeutics has raised $22.04 million across 6 funding rounds from investors including Finnvera, Business Finland and Tesi. Aurealis Therapeutics offers products and services including AUP-16 and AUP-55. Aurealis Therapeutics operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Basel, Switzerland
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$22.04 M (USD)
in 6 rounds
-
Latest Funding Round
$9 M (USD), Series B
Nov 15, 2024
-
Investors
Finnvera
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aurealis Therapeutics
Aurealis Therapeutics offers a comprehensive portfolio of products and services, including AUP-16 and AUP-55. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapy for treating chronic wounds like diabetic foot ulcers
Therapy for addressing various cancers such as ovarian and bladder
Funding Insights of Aurealis Therapeutics
Aurealis Therapeutics has successfully raised a total of $22.04M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $9 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series B — $9.0M
-
First Round
First Round
(05 Dec 2013)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2024 | Amount | Series B - Aurealis Therapeutics | Valuation |
investors |
|
| Jun, 2021 | Amount | Series A - Aurealis Therapeutics | Valuation | Tesi |
|
| Aug, 2017 | Amount | Series A - Aurealis Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Aurealis Therapeutics
Aurealis Therapeutics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Finnvera, Business Finland and Tesi. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investment firm
|
Founded Year | Domain | Location | |
|
Early-stage startups are supported through investments and collaboration by Nostetta Ventures.
|
Founded Year | Domain | Location | |
|
Loans, investments, and financial services are provided to businesses.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aurealis Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Aurealis Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aurealis Therapeutics Comparisons
Competitors of Aurealis Therapeutics
Aurealis Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aurealis Therapeutics
Frequently Asked Questions about Aurealis Therapeutics
When was Aurealis Therapeutics founded?
Aurealis Therapeutics was founded in 2015.
Where is Aurealis Therapeutics located?
Aurealis Therapeutics is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Who is the current CEO of Aurealis Therapeutics?
Juha Yrjanheikki is the current CEO of Aurealis Therapeutics.
Is Aurealis Therapeutics a funded company?
Aurealis Therapeutics is a funded company, having raised a total of $22.04M across 6 funding rounds to date. The company's 1st funding round was a Series A of $5.8M, raised on Dec 05, 2013.
What does Aurealis Therapeutics do?
Aurealis Therapeutics was founded in 2015 and is based in Basel, Switzerland. Focus is placed on the biotechnology sector, where cell and gene therapy platforms are developed to address chronic wounds, cancer, and inflammatory diseases. Operations involve research into curative treatments for these conditions and other unmet medical needs. Leadership is provided by CEO Juha Yrjanheikki, with activities centered on advancing therapeutic solutions in the field.
Who are the top competitors of Aurealis Therapeutics?
Aurealis Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Aurealis Therapeutics offer?
Aurealis Therapeutics offers AUP-16 and AUP-55.
Who are Aurealis Therapeutics's investors?
Aurealis Therapeutics has 4 investors. Key investors include Finnvera, Business Finland, Tesi, and Nostetta Ventures.